Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nurix Therapeutics

11.64
+0.18001.57%
Volume:2.15M
Turnover:25.45M
Market Cap:887.38M
PE:-4.15
High:12.38
Open:11.97
Low:11.64
Close:11.46
Loading ...

Company Profile

Company Name:
Nurix Therapeutics
Exchange:
NASDAQ
Establishment Date:
2009
Employees:
286
Office Location:
1700 Owens Street,Suite 205,San Francisco,California,United States
Zip Code:
94158
Fax:
415 525 4200
Introduction:
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing DeTIL-0255, a drug-enhanced investigational cell therapy product that uses NX-0255 ex vivo to enhance tumor infiltrating lymphocytes propagation and phenotypic characteristics. The company has a strategic collaboration agreement with Gilead Sciences, Inc. to discover, develop, and commercialize a pipeline of protein degradation drugs for patients with cancer and other challenging diseases; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.

Directors

Name
Position
Arthur T. Sands
President, Chief Executive Officer and Director
David Lacey
Director
Jeffrey Tong
Director
Julia P. Gregory
Director
Leon Chen
Director
Lori A. Kunkel
Director

Shareholders

Name
Position
Arthur T. Sands
President, Chief Executive Officer and Director
Hans van Houte
Chief Financial Officer
Christine Ring
General Counsel and Secretary
Gwenn Hansen
Chief Scientific Officer
Pierre Beaurang
Chief Business Officer